SynthesisThe Cochrane database of systematic reviews2011
Progesterone for acute traumatic brain injury.
Synthesis in The Cochrane database of systematic reviews, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Progesterone for acute traumatic brain injury.The Cochrane database of systematic reviews · 2016Pooled it
- Trial protocol OPPTIMUM-- does progesterone prophylaxis for the prevention of preterm labour improve outcome?BMC pregnancy and childbirth · 2012Trial
- Medical Management of the Severe Traumatic Brain Injury Patient.Neurocritical care · 2017Review
- Neuroprotective Role of Steroidal Sex Hormones: An Overview.CNS neuroscience & therapeutics · 2016Review
- Pgrmc1/BDNF Signaling Plays a Critical Role in Mediating Glia-Neuron Cross Talk.Endocrinology · 2016Article
- Sex differences in cognitive impairment and Alzheimer's disease.Frontiers in neuroendocrinology · 2014Review
- Article
- Progesterone-induced neuroprotection: factors that may predict therapeutic efficacy.Brain research · 2013Review
- Progesterone, brain-derived neurotrophic factor and neuroprotection.Neuroscience · 2013Review
- Animal models of traumatic brain injury.Nature reviews. Neuroscience · 2013Review
- Progesterone and neuroprotection.Hormones and behavior · 2013Review
- Guilty molecules, guilty minds? The conflicting roles of the innate immune response to traumatic brain injury.Mediators of inflammation · 2012Article
- Geriatric Traumatic Brain Injury in China.Current translational geriatrics and experimental gerontology reports · 2012Review
- Is progesterone a worthy candidate as a novel therapy for traumatic brain injury?Dialogues in clinical neuroscience · 2011Review
- Factors prognosticating the outcome of decompressive craniectomy in severe traumatic brain injury: A Malaysian experience.Asian journal of neurosurgeryArticle
Corrections and comments
- Updated by
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTraumatic brain injury is a leading cause of death and disability. Progesterone is a potential neuroprotective drug to treat patients with traumatic brain injury.
objectivesTo assess the effectiveness and safety of progesterone in people with acute traumatic brain injury (TBI). SEARCH STRATEGY: We searched: the Cochrane Injuries Group's Specialised Register (to April 2010), Cochrane Central Register of Controlled Trials 2010, Issue 1 (The Cochrane Library), MEDLINE (Ovid) (1950 to April week 1 2010), EMBASE (Ovid) (1980 to week 14 2010), LILACS (to 17 April 2010 ), Zetoc (to 21 April 2010), Clinicaltrials.gov (17 April 2010 ), Controlled-trials.com (17 April 2010). SELECTION CRITERIA: We included published and unpublished randomised controlled trials (RCTs) of progesterone versus no progesterone (or placebo) for the treatment of acute TBI. DATA COLLECTION AND ANALYSIS: Two authors independently screened search results to identify the full texts of potentially relevant studies for inclusion. From the results of the screened searches two authors independently selected trials meeting the inclusion criteria, with no disagreement. MAIN
resultsThree studies were included with 315 patients. All three studies reported the effects of progesterone on mortality. The pooled relative risk (RR) for mortality at end of follow-up is 0.61, 95% confidence interval (CI) 0.40 to 0.93. Three studies measured disability and found the RR of death or severe disability in patients treated with progesterone was 0.77, 95% confidence interval (CI) 0.62 to 0.96. Two studies presented data on intracranial pressure and adverse events. One study presented blood pressure and temperature data. There was no substantial evidence for the presence of heterogeneity. AUTHORS'
conclusionsCurrent clinical evidence from three small RCTs indicates progesterone may improve the neurologic outcome of patients suffering TBI. This evidence is still insufficient and further multicentre randomised controlled trials are required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.